Latest news with #medicalcannabis
Yahoo
2 days ago
- Business
- Yahoo
Cronos Group (CRON) Expands its Reach to Europe with a New Partnership
Cronos Group Inc. (NASDAQ:CRON) is one of the . On July 2, Cronos Group Inc. (NASDAQ:CRON) announced expanding its reach in Europe by forging a new partnership with Dascoli Pharma AG. Dascoli is a leader in distributing medical cannabis in Switzerland. As per the partnership, the company's Peace Naturals medical cannabis flower will be sold through Dascoli's Swiss network. The following strains of Peace Naturals would be available for patients in Switzerland, including GMO Cookies, Space Cake, Atomic Sour Grapefruit, Sonic Lemon Fuel, and Wedding Cake. This partnership aligns with Cronos Group Inc. (NASDAQ:CRON)'s strategy to increase its presence in key medical cannabis markets. A close up of cannabis plants growing in an outdoor facility, symbolizing the product of the cannabinoid company. Cronos Group Inc. (NASDAQ:CRON) is a global cannabis company that develops and sells a variety of cannabinoid products. While we acknowledge the potential of CRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Rising Clinical Trials, R&D Activities, and Commercialization of Cannabis-based Indications
Global medical cannabis market to hit USD 68.6 billion by 2033, growing at a 7.1% CAGR. Key growth drivers include increasing legalization and therapeutic use for conditions like chronic pain and epilepsy. North America leads due to progressive regulations. Top players like Canopy Growth and GW Pharmaceuticals drive innovation in the sector. Medical Cannabis Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Medical Cannabis Market Report 2025-2033" report has been added to global medical cannabis market size reached USD 37.0 Billion in 2024. Looking forward, the publisher expects the market to reach USD 68.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.1% during 2025-2033. The increasing product use in treating substance use disorders, the exploration of products for chronic inflammatory conditions, the rising product demand for gastrointestinal disorders, and the rising demand for CBD-based products are some of the factors propelling the market. The global market is majorly driven by the increasing acceptance of the product for medicinal purposes. In line with this, the expanding legalization of the product is significantly contributing to the market. Furthermore, the rising awareness of the potential therapeutic benefits of the product is positively influencing the market. Apart from this, the rapid advancements in cannabis research and medical studies are offering numerous opportunities for the market. Moreover, the growing prevalence of chronic pain and other medical conditions treatable with the product is catalyzing the market. Besides, the escalating aging population seeking alternative treatments for age-related ailments is propelling the market. The opioid crisis and the search for safer pain management options are bolstering the market. Additionally, the increasing demand for natural and plant-based medicines is providing a boost to the market. Competitive Landscape: Top companies are strengthening the market by leveraging their resources, expertise, and brand recognition. These companies invest heavily in research and development to create innovative cannabis-based products with consistent quality and efficacy. They expand their presence in key markets through strategic partnerships and acquisitions, driving consumer awareness and accessibility. Their established distribution networks enable the widespread availability of medical cannabis products, reaching a broader patient base. Furthermore, these companies also engage in educational initiatives to raise awareness among healthcare professionals and the general public about the therapeutic potential of medical cannabis. Their efforts to comply with regulatory standards and maintain product safety build trust and credibility in the industry. By setting high industry standards and fostering best practices, these companies contribute to the market growth, leading the way for continued expansion and acceptance of medical cannabis as a legitimate and effective treatment option. North America exhibits a clear dominance, accounting for the largest medical cannabis market shareNorth America is fostering the market growth due to its progressive regulatory environment, increasing acceptance, and widespread legalization across various states and countries in the region. In particular, the United States and Canada have been at the forefront of the medical cannabis movement, with many states and provinces legalizing medical cannabis for therapeutic use. The growing awareness and acceptance of medical cannabis have increased patient demand as individuals seek alternative treatments for various medical conditions. This increasing demand, in turn, has spurred investments in research, development, and commercialization of medical cannabis products, driving market well-established pharmaceutical companies and research institutions in North America have accelerated the development of standardized and regulated cannabis-based medications, further propelling market expansion. The evolving legal landscape, coupled with a strong consumer base and supportive healthcare policies, positions North America as a significant driving force behind the market's global Cannabis Market Trends/Drivers: Rising clinical trials, research and development (R&D) activities, and commercialization of cannabis-based indicationsThe rising clinical trials, research and development (R&D) activities, and commercialization of cannabis-based indications are fostering the market. With increasing acceptance and legalization, there is a growing interest among researchers, pharmaceutical companies, and medical professionals to explore the potential therapeutic benefits of the product. Clinical trials and research studies are essential to provide scientific evidence supporting the efficacy and safety of cannabis-based treatments for various medical conditions. As more positive results emerge from these studies, confidence in medical cannabis as a legitimate treatment options increases, leading to wider adoption. Furthermore, commercializing cannabis-based indications has seen substantial investments from pharmaceutical companies and startups. The development of standardized cannabis-based pharmaceutical products offers more consistent dosing, quality control, and regulatory compliance, further legitimizing the product in the healthcare industry. As the product becomes more firmly integrated into mainstream medicine, the market is expected to expand, attracting more patients, healthcare providers, and investors. This positive momentum in research, development, and commercialization fuels the disposable incomes of the consumersThe inflating disposable incomes of the consumers are favorably impacting the market. As disposable incomes rise, consumers have more financial capacity to spend on healthcare, including alternative and complementary treatments. With increased purchasing power, individuals are more likely to explore and invest in the product for various health conditions. Medical cannabis, which may not be covered by insurance in some regions, can become a viable option for consumers with higher disposable incomes. Inflating disposable incomes also contribute to a shift in consumer preferences towards more holistic and natural health remedies. As individuals prioritize their well-being, they seek alternative treatments beyond traditional pharmaceuticals, leading to increased demand for the product. Additionally, higher disposable incomes allow consumers to afford these products that may be of higher quality or from reputable sources, boosting the premium segment of the emergence of new cannabis-based pharmaceutical productsThe emergence of new cannabis-based pharmaceutical products is bolstering the market. As research and clinical trials continue to explore the therapeutic potential of cannabinoids and other cannabis-derived compounds, pharmaceutical companies are developing innovative cannabis-based medications. These new pharmaceutical products undergo rigorous testing and regulatory approvals, instilling confidence in medical professionals and patients about their safety and efficacy. As a result, more healthcare providers are open to prescribing cannabis-based medications for various medical conditions, thus driving market adoption. The development of standardized cannabis-based pharmaceuticals also addresses concerns about dosage consistency and quality control, making them more reliable and appealing to patients and healthcare providers. Moreover, the emergence of new cannabis-based medications expands the potential applications of medical cannabis in treating a wide range of conditions, from chronic pain and neurological disorders to mental health ailments. Key Attributes: Report Attribute Details No. of Pages 125 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $37 Billion Forecasted Market Value (USD) by 2033 $68.6 Billion Compound Annual Growth Rate 7.1% Regions Covered Global Detailed Profiles of All Major Companies Canopy Growth Corporation GW Pharmaceuticals, plc Aurora Cannabis, Inc. Aphria, Inc. MedReleaf Corporation Insys Therapeutics, Inc. CanniMed Therapeutics, Inc. Cara Therapeutics, Inc. United Cannabis Corporation Medical Cannabis Industry Segmentation:Breakup by Species: Indica Sativa Hybrid Breakup by Derivatives: Cannabidiol (CBD) Tetrahydrocannabinol (THC) Others Breakup by Application: Cancer Arthritis Migraine Epilepsy Others Breakup by End-Use: Pharmaceutical Industry Research and Development Centres Others Breakup by Route of Administration: Oral Solutions and Capsules Vaporizers Topicals Others Breakup by Region: North America United States Canada Asia-Pacific Europe Germany France Italy Spain Netherlands Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Medical Cannabis Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
7 days ago
- Health
- Medscape
Why Is Medical Cannabis Missing From Med School Curriculum?
At last count, 48 US states, Washington DC, and 3 territories have legalized cannabis for medical/therapeutic purposes, and 24 for adult recreational use. In 2020, at least 8.3 million Americans acknowledged using medical cannabis; many of the same patients also reported mixed (ie, medicinal/recreational) use. Clinical education has not caught up. There are 19 cannabis education certificate and/or master's level programs offered in colleges, universities, and graduate schools in 14 US states, meaning that only about one third of the 48 states that have legalized medicinal cannabis have some sort of college or graduate-level curriculum to support patients. The dearth of cannabis education has also left a large percentage of the more than 1 million practicing physicians in the US — and concurrently, most future prescribers — without a framework to leverage what has the potential to become one of the most important tools at their disposal. Leah Sera, PharmD, is associate professor and the inaugural program director of the nation's first Master of Science in Medical Cannabis Science and Therapeutics program at the University of Maryland (UMD) School of Pharmacy in Baltimore. Sera explained the impetus behind UMD's program (which launched in August 2019) was the concerns voiced by health professionals; not only were they not learning about cannabis medicine and the endocannabinoid system in academic programs, but more importantly, they lacked the knowledge to help patients coming to them with questions. 'I think that it's important for health professional educational programs to incorporate cannabis medicine into their curricula so that when we graduate new generations of healthcare providers, they're better equipped to really engage with a public who clearly wants more information — both to keep them safe and help improve their lives,' she said. Medical literature has underscored that medical students feel the same. A 2019 survey of medical school students indicated that although participants expressed mixed feelings about medicinal cannabis, the majority said they lacked adequate knowledge about its therapeutic applications, research, and science and instead relied on anecdotal evidence and social media for information. The Endocannabinoid System Arguably, politics have played a large role in slowing broad acceptance of the medicinal benefits of cannabis (eg, fearmongering, the war on drugs), and it is still considered a Schedule 1 drug. These factors are also believed to have contributed to the lack of inclusion in medical school curriculum. 'What it means for cannabis to be a Schedule 1 substance is that the federal government says that cannabis does not have a currently accepted medical use and the highest risk of abuse,' said Sera. 'Although there's been a lot of cannabis research both within and outside the US, it's very difficult to do gold standard randomized, controlled trials with any Schedule 1 drug.' 'Until very recently (and it may be occurring still), a lot of medical and nursing programs taught that cannabis is bad, has no therapeutic benefits, and it's highly addictive,' added Nishi Whiteley, cofounder and chief operating officer of CReDO Science, a science and research organization geared toward education, cannabis product optimization, and clinical consultation. 'There's been an active campaign to malign cannabis, which is an enormous disservice to the patient and to the medical professional who needs to have more tools in their toolbox,' she said. Despite these challenges, decades of scientific research have consistently shown that the endocannabinoid system helps modulate a wide range of physiologic processes (eg, pain, inflammation, mood, metabolism, and neuroprotection) through its interaction with the major systems in the body, including the nervous, immune, and endocrine systems and digestive symptoms. This is a key reason why cannabis researchers and specialists have argued for its inclusion within medical education programs. 'Every place we've looked, in whatever physiological system, the endocannabinoid system has a role as a homeostatic regulator,' said Ethan Russo, MD, a board-certified neurologist, psychopharmacology researcher, and cofounder/CEO of CReDO Science. 'We now understand that there are endogenous cannabinoids that are similar in structure to what we see in cannabis,' said Reggie Gaudino, PhD, a molecular geneticist and director of the Cannabis Research Institute at the University of Illinois Chicago. 'The endocannabinoid system is like the one ring to rule them all,' he said. 'It interacts through all other biochemical pathways and systems in the body to help keep our different processes in balance. Without understanding that system, we create other problems.' Just the Basics These cannabis experts said that at the very least, practicing and future prescribers need a foundational education that might include an overview of the endocannabinoid system, how it applies to disease processes, and its major components. 'The endocannabinoid system is a good starting point; it's how we are used to learning about medications and how biological systems are altered from disease or medication or other treatments,' said Sera. She explained that this provides a foundation for discussions about the pharmacology of cannabinoids — chemicals within the cannabis plant that have biologic activity in humans and other animals — and how they interact with the endocannabinoid system to produce downstream effects on other organs. Sera also said that it is important for future prescribers to learn how to interpret different types of medical literature and cannabis studies despite methodological concerns that have plagued the industry and the lack of studies on specific products available in medical dispensaries. The same is true for counteracting cannabis hysteria in mainstream media every time a new study comes out, said Russo. 'Medical students need to be aware that real issues can arise with cannabis and its potential abuse, which does happen,' he explained. 'But the other side of the coin is therapeutics, which is quite distinct in terms of intent and dosages, ie, there's a distinction between a small dose for therapeutic purposes and a large dose that may produce harm.' Importantly, this fact has often been overlooked in alarmist headlines and stories that have gained the most traction. Bridging the Gap Today, the gap between educational needs and educational reality is large. To address this, Russo and Whiteley said they developed an online, 40-hour advanced medical cannabis certificate program for practicing clinicians. For professionals interested in learning how to address patient questions in an informed manner, they also created a Foundations of Cannabis Therapeutics course. Though future prescribers can certainly benefit from these sorts of online foundational courses, the dearth of cannabis education within medical schools has left a large knowledge and practice deficit. Dustin Sulak, DO, an integrative medicine specialist, cannabis expert, and founder of Intergr8 Health and a medical cannabis education resource in Falmouth, Maine, considers cannabis medicine revolutionary in that it actually alters the way the medicine is practiced. 'Cannabis medicine is a paradigm shift away from single-molecule interventions that have single physiologic targets toward more complex botanical treatments that target many things in the body — most of all, interfacing with the endocannabinoid system,' said Sulak. He used the example of managing pain, sleep, spasticity, and depression all at the same time with the same treatment. 'For any field of medicine to fail to take into consideration the role of the endocannabinoid system in pathophysiology is a shortcoming and a missed opportunity for interventions that improve symptoms and potentially, a cure,' he said. There is a broader paradigm shift that's needed, one that requires a new mindset, especially within the medical education and practice arena. 'I think of myself as a patient advocate, not a cannabis advocate,' said Sera. 'Cannabis is a potentially powerful tool for some patients that can improve their lives; it's not about the plant itself.' Russo is chief medical officer for Indira Pharmaceuticals and receives advisory fees from Carnada. Sulak is equity owner of Whiteley, Gaudino, and Sera reported having no relevant financial relationships.
Yahoo
12-07-2025
- Business
- Yahoo
BrewDog co-founder plans cannabis market dominance in new venture
One of the founders of BrewDog is targeting domestic dominance with a new business, planning to invest £20m into his new medical cannabis company. Martin Dickie, who founded the alcohol and bars firm with James Watt nearly 20 years ago, now runs Waterside Pharmaceuticals. A licence was granted by the Home Office last year to cultivate medical cannabis, with the firm describing their set-up as a tech-led vertical farm, with controlled environments and sustainable operations. The first harvest, from a farm near Newburgh, Aberdeenshire, is expected to yield up to 9kg of medical cannabis. However, plans are to expand that to 200kg this year, with ambitions to continually scale up and grow the business over the coming years. 'Our aim is to become the UK market leader in medical cannabis,' Mr Dickie said. 'We have ambitious plans to expand the business, creating up to 100 new jobs in the local economy and investing around £20m over the next five years. 'Our longer-term ambitions involve building a second facility co-located with a renewable energy source, minimising our environmental impact, creating jobs and diversifying the rural economy.' Doctors in the UK have been allowed to prescribe cannabis-based medicines since 2018, for some conditions. The company estimates 50,000 to 60,000 patients benefit from them, with the number growing yearly. Plants in the controlled environment are subject to 12 hours of artificial light and 12 hours of darkness for optimal growth. Waterside plans to open a second facility over the longer term. Chief operating officer Morag Thomas, who also previously worked at BrewDog, claimed Waterside had a 'premium product' in part through no use of pesticides and fungicides, the Times reported. Mr Dickie reportedly retains ownership of around 20 per cent of BrewDog. Waterside did not respond to a request for comment over expansion plans and industry challenges. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Independent
11-07-2025
- Business
- The Independent
BrewDog co-founder plans cannabis market dominance in new venture
One of the founders of BrewDog is targeting domestic dominance with a new business, planning to invest £20m into his new medical cannabis company. Martin Dickie, who founded the alcohol and bars firm with James Watt nearly 20 years ago, now runs Waterside Pharmaceuticals. A licence was granted by the Home Office last year to cultivate medical cannabis, with the firm describing their set-up as a tech-led vertical farm, with controlled environments and sustainable operations. The first harvest, from a farm near Newburgh, Aberdeenshire, is expected to yield up to 9kg of medical cannabis - but plans are to expand that to 200kg this year, with ambitions to continually scale-up and grow the business over the coming years. 'Our aim is to become the UK market leader in medical cannabis,' Mr Dickie said. 'We have ambitious plans to expand the business, creating up to 100 new jobs in the local economy and investing around £20 million over the next five years. 'Our longer-term ambitions involve building a second facility co-located with a renewable energy source, minimising our environmental impact, creating jobs and diversifying the rural economy.' Doctors in the UK have been allowed to prescribe cannabis-based medicines since 2018, for some conditions. The company estimates 50,000 to 60,000 patients benefit from them, with the number growing yearly. Plants in the controlled environment are subject to 12 hours of artificial light and 12 hours of darkness, for optimal growth. Waterside plan to open a second facility over the longer term. Chief operating officer Morag Thomas, who also previously worked at BrewDog, claimed Waterside had a 'premium product' in part through no use of pesticides and fungicides, the Times reported. Mr Dickie reportedly retains ownership of around 20 per cent of BrewDog. Waterside did not respond to a request for comment over expansion plans and industry challenges.
